Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection.
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerIdentification of Posttranslational Modification-Dependent Protein Interactions Using Yeast Surface Displayed Human Proteome LibrariesHigh-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies.Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodiesHuman antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.Phage-display selection on tumor histological specimens with laser capture microdissection.Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells.A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth.Selection of antibodies against a single rare cell present in a heterogeneous population using phage display.Biopanning Phage-Display Libraries on Small Tissue Sections Captured by Laser Capture MicrodissectionNanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.Selection and characterization of cell binding and internalizing phage antibodies.Screening and selection of peptides specific for esophageal cancer cells from a phage display peptide library.Selection of cell-type specific antibodies on tissue-sections using phage displaySelection strategies for anticancer antibody discovery: searching off the beaten path.Combining Phage and Yeast Cell Surface Antibody Display to Identify Novel Cell Type-Selective Internalizing Human Monoclonal AntibodiesA novel excision selection method for isolation of antibodies binding antigens expressed specifically by rare cells in tissue sectionsMicroselection--affinity selecting antibodies against a single rare cell in a heterogeneous population.Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.Paradigm shift in bacteriophage-mediated delivery of anticancer drugs: from targeted 'magic bullets' to self-navigated 'magic missiles'.Raising antibodies against circulating foetal cells from maternal peripheral blood.Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragmentNovel human single chain antibody fragments that are rapidly internalizing effectively target epithelioid and sarcomatoid mesotheliomasModular Construction of Large Non-Immune Human Antibody Phage-Display Libraries from Variable Heavy and Light Chain Gene Cassettes.Combine Phage Antibody Display Library Selection on Patient Tissue Specimens with Laser Capture Microdissection to Identify Novel Human Antibodies Targeting Clinically Relevant Tumor Antigens.Cell-type specific potent Wnt signaling blockade by bispecific antibody.Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins.Identification of oligopeptide binding to colon cancer cells separated from patients using laser capture microdissection
P2860
Q26738703-C38FE4E8-3129-4625-8594-6ED37701271DQ26859524-A6E4BEE5-77A3-47A1-B332-E971AEBD42D1Q30605298-B590A346-8D69-4344-BDC6-9F031E69FC98Q33322420-A11E5B30-DFA3-40B9-A195-21CC5284DA8AQ33409529-49B5B68A-77C2-4B3A-B27B-AE8D4664C96EQ33470770-2797C57F-97FC-4A57-B27C-DDFC1EA075E0Q33620053-25D92AE5-19CE-4561-9788-8AFCDE1D9AADQ33634142-A71ADAA7-A672-4529-B44F-8C156B9A0871Q33859354-F6A6CB96-F9B8-4CF7-AD66-A052F36B4E8AQ33984770-48A58A20-76A9-4C03-9253-F7101BDD675CQ34209735-9F3677C4-EE54-4396-9CEE-8F09F0A2BEFDQ34280931-FDC9EEF6-7E03-4D7E-B464-9BA5D976DCAAQ35159395-90945D2A-AAD8-4C50-869A-75BE2DD7BF89Q35586630-ACE8AF03-C543-4101-9C64-D8212FEACBB7Q35589427-57ED253F-8338-4E3E-8757-B1BA37E7E658Q35659188-92B56256-5775-4280-BF24-48184CEAA153Q36332226-BDAA6C67-A359-4AC6-8A33-2A70E1B3C4EEQ37295707-4600B211-2EFD-4B3C-B411-C9FE33695B9DQ37452241-1A7ED804-4190-451C-8631-0D56F9462031Q38910806-AFB7B883-950A-4BE9-B57A-3067C6460DE0Q39198232-54DA24D7-5343-43BB-BFB9-AFB98E934AC0Q39417962-3B8B9307-B82C-4804-B267-08EBDDE47452Q42711592-6724504F-D5E2-4AA9-869A-092A3DA56B88Q46499056-F096DA11-037C-4F4B-B778-A58171BC688EQ47233474-A3FDE280-BE31-42C8-83DF-83D7756E57B1Q49292906-FFDDA67D-E40A-4922-84FE-C6820B3052B5Q50041898-DFBE99DD-BB93-4F73-8A8A-B155F0101E4AQ56893974-29D464EE-21CF-447D-92B7-7A7E89F380B0
P2860
Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Identification of clinically s ...... laser capture microdissection.
@ast
Identification of clinically s ...... laser capture microdissection.
@en
Identification of clinically s ...... laser capture microdissection.
@nl
type
label
Identification of clinically s ...... laser capture microdissection.
@ast
Identification of clinically s ...... laser capture microdissection.
@en
Identification of clinically s ...... laser capture microdissection.
@nl
prefLabel
Identification of clinically s ...... laser capture microdissection.
@ast
Identification of clinically s ...... laser capture microdissection.
@en
Identification of clinically s ...... laser capture microdissection.
@nl
P2093
P2860
P1476
Identification of clinically s ...... laser capture microdissection.
@en
P2093
Adam Sassoon
Jeff P Simko
Weiming Ruan
P2860
P304
P356
10.1074/MCP.M600246-MCP200
P577
2006-09-18T00:00:00Z